Monday, 28 May 2018
Latest news
Main » Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Downgraded to Neutral at Robert W. Baird

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Downgraded to Neutral at Robert W. Baird

11 August 2017

Achillion Pharma had 20 analyst reports since August 13, 2015 according to SRatingsIntel. ACHN's value Change from Open was at 2.34% with a Gap of 17.21%.

Achillion Pharmaceuticals, Inc. shares increased 19.95 percent over the past week and rose 6.89 percent over the previous month. (NASDAQ:ACHN) for 115,458 shares. On Friday, September 23 the stock rating was initiated by Wedbush with "Outperform". As per Wednesday, May 4, the company rating was maintained by Leerink Swann. More interesting news about Achillion Pharmaceuticals, Inc. Analysts giving shares a rating of 1 or 2 would be indicating a Buy. The firm earned "Neutral" rating on Friday, November 4 by Chardan Capital Markets. The firm has "Hold" rating by Chardan Capital Markets given on Wednesday, August 9. See Achillion Pharmaceuticals, Inc. City Holdings reported 275 shares stake. Pub Employees Retirement Association Of Colorado holds 0% or 27,160 shares in its portfolio. (CRY)'s stock rose 5.80%. Cryolife Inc. now has $612.06 million valuation. Pfizer Inc. (NYSE:PFE) has declined 2.76% since August 9, 2016 and is downtrending. About 85,241 shares traded. Unity Bancorp, Inc. (UNTY) has risen 54.08% since August 10, 2016 and is uptrending. It has outperformed by 43.95% the S&P500.

Among 21 analysts covering Kellogg Company (NYSE:K), 9 have Buy rating, 1 Sell and 11 Hold. Therefore 46% are positive. (NASDAQ:ACHN) on Tuesday, September 8 to "Buy" rating. The firm has "Equal-Weight" rating by Barclays Capital given on Friday, February 10. Blair William And Communication Il owns 42,400 shares. The company was upgraded on Tuesday, September 8 by UBS. As per Thursday, February 16, the company rating was downgraded by Jefferies.

Investors sentiment decreased to 1.41 in 2016 Q4. Its down 0.43, from 1.52 in 2016Q3. Moreover, Banc Funds Co Llc has 0.44% invested in the company for 653,769 shares. 5,372 were reported by Blackrock Japan. EPS breaks down the profitability of the company on a single share basis. Raymond James Associates accumulated 0% or 102,965 shares. Td Asset Mngmt holds 6.42 million shares.

More news: Jeffress: God sanctions 'fire and fury'

ATR value of company was 0.29. Alps Advisors Inc invested in 0% or 131,351 shares. Princeton Alpha L P has 29,577 shares for 0.03% of their portfolio. (NYSE:PFE). 204,130 are owned by Novare Capital Mgmt Ltd Limited Liability Company.

More recent Achillion Pharmaceuticals, Inc. On the other side, sales forecasts for the current quarter are $0 Million. The insider HILL CHARLES H sold 36,000 shares worth $1.23 million. It also reduced Vse Corp. 22 funds opened positions while 49 raised stakes. Financial Architects holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) remains a cheap stock. The mean revenue estimate is $2.5 Million. Great West Life Assurance Com Can reported 8,721 shares stake. Wellington Llp stated it has 0% in Achillion Pharmaceuticals, Inc.

A total of 5 analysts have released a research note on ACHN. Renaissance Ltd Llc, New York-based fund reported 945,189 shares. Adirondack Rech Management reported 13,556 shares or 0.2% of all its holdings. FBR Capital initiated Achillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Tuesday, August 8th.

More news: Trump declares opioid crisis is national emergency, pledges more money, attention

Media coverage about Achillion Pharmaceuticals (NASDAQ:ACHN) has been trending positive on Thursday, according to Accern Sentiment. Kcg Holdg invested in 0.01% or 57,429 shares. Da Davidson And owns 0.01% invested in Achillion Pharmaceuticals, Inc. Grp accumulated 67,382 shares. 25,515 are owned by Parametric Port Associates Ltd Liability Corporation.

About 24.10M shares traded or 1859.35% up from the average. For the current quarter Achillion Pharmaceut (NASDAQ:ACHN) has high EPS estimates of $-0.18 in contradiction of low EPS estimates of $-0.2. It has underperformed by 64.31% the S&P500.

Relative strength index (RSI-14) for Achillion Pharmaceuticals, Inc. The company has market cap of $650.12 million.

Milind Deshpande, president and chief executive officer of Achillion, said that in addition to trying to develop a treatment for PNH, the company is also working on a drug to combat another rare immunological disease, C3G. It now has negative earnings.

More news: Deathmatch in Two Flavors Coming Soon in Arcade Mode

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Downgraded to Neutral at Robert W. Baird